AbbVie (NYSE: ABBV) is expected to see faster growth in the next five years, with a focus on immunology, neuroscience, and oncology. With $7.2 billion in cash, the company may pursue more acquisitions in these areas. Revenue is projected to grow at a compound annual rate of 7-9% from 2024-2029, reaching between $75.4 billion and $83.1 billion. Shareholders can anticipate dividend increases, but at a slower pace. The biggest risk for AbbVie is research and development investments not aligning with future markets. Overall, the company is set to expand and reduce its long-term debt by 2029.

Investors should consider the investment potential of AbbVie, as it is not among the 10 best stocks identified by The Motley Fool Stock Advisor team. This service has outperformed the S&P 500 since 2002, offering guidance on portfolio building and monthly stock picks. While AbbVie may not be a top pick, opportunities for significant returns exist with other recommended stocks.

Read more at NASDAQ.: Where Will AbbVie Be in 5 Years?